Lactose modifications enhance its drug performance in the novel multiple dose Taifun ® DPI

• Published in: European journal of pharmaceutical sciences 2002-09, Vol.16 (4), p.313-321
• Main Authors: Harjunen, Päivi, Lehto, Vesa-Pekka, Martimo, Krista, Suihko, Eero, Lankinen, Tapio, Paronen, Petteri, Järvinen, Kristiina
• Format: Article
• Language: English
• Subjects: Budesonide; Budesonide - administration & dosage; Budesonide - chemistry; Calorimetry, Differential Scanning; Chromatography, High Pressure Liquid; Drug Carriers - administration & dosage; Drug Carriers - chemistry; Drug Delivery Systems - instrumentation; Drug Stability; Drug Storage; Inhalation powder; Lactose; Lactose - administration & dosage; Lactose - chemistry; Metered Dose Inhalers; Models, Biological; Multiple dose DPI; Particle Size; Powders; Spray drying; Taifun
• ISSN: 0928-0987; 1879-0720
• DOI: 10.1016/S0928-0987(02)00126-4

Drug–carrier particle interactions greatly affect the detachment of drug from the carrier in inhalation powders. In this study, a novel multiple dose, reservoir-based Taifun ® was used as a dry powder inhaler, and the effects of carrier physical properties were evaluated on the pulmonary deposition of budesonide, along with physical stability of the inhalation powder. In this study, untreated commercial preparation of α-lactose monohydrate, highly amorphous spray dried lactose, crystallized spray dried lactose, Flowlac-100 ® and Flowlac-100 ® mixed with crystalline micronized lactose were used as carriers. Dry powder formulations were prepared by the suspension method, where the budesonide–carrier ratio was 1:15.1 (w/w). Carriers and formulations were initially characterized, and again after 1 month’s storage at 40 °C/75% RH. The physical properties of the carriers strongly affected the pulmonary deposition of budesonide and the physical stability of the inhalation powder. Initially, amorphous contents of the carriers were 0–64%, but spontaneous crystallisation of the amorphous lactose occurred during storage and, thus all carriers were 100% crystalline after storage. When compared to an untreated α-lactose monohydrate, the highly amorphous spray dried lactose and Flowlac-100 ® did not improve aerosol performance of the inhalation powder. When crystalline spray dried lactose was used as a carrier, the highest RF% values were achieved, and RF % values did not alter during storage but the emitted budesonide dose was lower than the theoretical dose. When Flowlac-100 ® mixed with crystalline micronized lactose was used as a carrier, the emitted budesonide dose was close to the theoretical dose, and high RF % values were achieved but these changed during storage.